On Monday the Brazilian authorities, followed by the Philippines and Mexico, approved the withdrawal of the vaccine market of French pharmaceutical company Sanofi against dengue that has spread in Latin America.
According to the National Agency of health surveillance of Brazil, referenced by The Wall Street Journal, the price of the vaccine will be established by the government, however, the date of appearance of the drug in Brazil has not been proclaimed.
With the beginning of the year until mid-November in Brazil was recorded 1.5 million cases of infection, whereas last year during the same period, there were 555.400 patients.
The symptoms of dengue fever, which is transmitted through a mosquito bite, resulting in severe muscle pain, fever, headaches, vomiting, skin rashes and bleeding from the nose and gums. In rare cases symptoms may progress to severe bleeding, shock and even death.
In addition to dengue fever, Brazil is struggling with two other major epidemics that spread through mosquitoes: chikungunya, which causes fever and pain in the joints, and zika virus, which is associated with the development of microcephaly in infants.